196 related articles for article (PubMed ID: 33054128)
1. Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells.
Cieniewicz B; Uyeda MJ; Chen PP; Sayitoglu EC; Liu JM; Andolfi G; Greenthal K; Bertaina A; Gregori S; Bacchetta R; Lacayo NJ; Cepika AM; Roncarolo MG
Haematologica; 2021 Oct; 106(10):2588-2597. PubMed ID: 33054128
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives.
Chianese U; Papulino C; Megchelenbrink W; Tambaro FP; Ciardiello F; Benedetti R; Altucci L
Semin Cancer Biol; 2023 Jul; 92():84-101. PubMed ID: 37003397
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.
Memarian A; Nourizadeh M; Masoumi F; Tabrizi M; Emami AH; Alimoghaddam K; Hadjati J; Mirahmadian M; Jeddi-Tehrani M
Tumour Biol; 2013 Feb; 34(1):531-42. PubMed ID: 23179394
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SNHG1 overexpression regulates the proliferation of acute myeloid leukemia cells through miR-488-5p/NUP205 axis.
Bao XL; Zhang L; Song WP
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5896-5903. PubMed ID: 31298340
[TBL] [Abstract][Full Text] [Related]
6. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.
Matte-Martone C; Liu J; Zhou M; Chikina M; Green DR; Harty JT; Shlomchik WD
J Clin Invest; 2017 Jun; 127(7):2765-2776. PubMed ID: 28604385
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
Legrand O; Zompi S; Perrot JY; Faussat AM; Benderra Z; Chaoui D; Marie JP
Haematologica; 2004 Jan; 89(1):34-41. PubMed ID: 14754604
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.
Herbrich S; Baran N; Cai T; Weng C; Aitken MJL; Post SM; Henderson J; Shi C; Richard-Carpentier G; Sauvageau G; Baggerly K; Al-Atrash G; Davis RE; Daver N; Zha D; Konopleva M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326171
[TBL] [Abstract][Full Text] [Related]
9. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW; Sias-Garcia O; Daramola A; Wei H; Terrell M; Rashid R; Park WD; Duong K; Horton TM; Li F; Cherayil N; Koren JV; Gant VU; Junco JJ; Curry CV; Stevens AM; Lin CY; Yi JS
Blood Adv; 2021 Dec; 5(23):4864-4876. PubMed ID: 34543389
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
Kandeel EZ; Madney Y; Eldin DN; Shafik NF
Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
[TBL] [Abstract][Full Text] [Related]
11. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.
Dreyling MH; Schrader K; Fonatsch C; Schlegelberger B; Haase D; Schoch C; Ludwig W; Löffler H; Büchner T; Wörmann B; Hiddemann W; Bohlander SK
Blood; 1998 Jun; 91(12):4662-7. PubMed ID: 9616163
[TBL] [Abstract][Full Text] [Related]
12. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
15. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
[TBL] [Abstract][Full Text] [Related]
16. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.
Junge A; Zandi R; Havgaard JH; Gorodkin J; Cowland JB
Gene; 2017 Jun; 615():35-40. PubMed ID: 28322996
[TBL] [Abstract][Full Text] [Related]
17. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.
Tonks A; Pearn L; Musson M; Gilkes A; Mills KI; Burnett AK; Darley RL
Leukemia; 2007 Dec; 21(12):2495-505. PubMed ID: 17898786
[TBL] [Abstract][Full Text] [Related]
19. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
